Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Taysha Gene Therapies, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 131 | 1 | 127 | −3 |
| Shares | 167.5M | 546.4K | 166.9M | −74.2K (0.0%) |
| Value | $289.8M | $945.3K | $232.0M | −$56.8M (−19.7%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (22)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 4,569,678 | $6.35M | 0.02% |
| Superstring Capital Management LP | 755,599 | $1.05M | 1.25% |
| Nuveen, LLC | 546,414 | $759.5K | 0.00% |
| Jefferies Financial Group Inc. | 245,254 | $340.9K | 0.01% |
| XTX Topco Ltd | 203,129 | $282.3K | 0.01% |
| HRT Financial LP | 139,692 | $194.0K | 0.00% |
| BIT Capital GmbH | 117,062 | $162.7K | 0.02% |
| Franklin Resources Inc | 116,238 | $161.6K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 83,864 | $116.6K | 0.01% |
| Virtus Investment Advisers, Inc. | 72,957 | $101.4K | 0.03% |
| Jain Global LLC | 45,200 | $62.8K | 0.00% |
| Point72 (DIFC) Ltd | 15,528 | $21.6K | 0.00% |
| Two Sigma Securities, LLC | 13,071 | $18.2K | 0.00% |
| SIH Partners, LLLP | 12,173 | $16.9K | 0.00% |
| Catalyst Funds Management Pty Ltd | 11,900 | $16.5K | 0.00% |
| Camelot Portfolios, LLC | 11,000 | $15.3K | 0.01% |
| Bordeaux Wealth Advisors LLC | 10,109 | $14.1K | 0.00% |
| Caitong International Asset Management Co., Ltd | 814 | $1.13K | 0.00% |
| EverSource Wealth Advisors, LLC | 372 | $517 | 0.00% |
| Coldstream Capital Management Inc | 207 | $288 | 0.00% |
| True Wealth Design, LLC | 132 | $184 | 0.00% |
| Quadrant Capital Group LLC | 2 | $3 | 0.00% |
Sold out (25)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 5,000,000 | $8.65M |
| VR Adviser, LLC | 3,225,180 | $5.58M |
| Norges Bank | 1,461,120 | $2.53M |
| Acuta Capital Partners, LLC | 884,244 | $1.53M |
| Renaissance Technologies LLC | 878,448 | $1.52M |
| Rafferty Asset Management, LLC | 252,257 | $436.4K |
| Squarepoint Ops LLC | 211,842 | $366.5K |
| Jane Street Group, LLC | 169,575 | $293.4K |
| Marshall Wace, LLP | 138,111 | $238.9K |
| Virtu Financial LLC | 107,544 | $186.0K |
| Aquatic Capital Management LLC | 78,246 | $135.4K |
| LPL Financial LLC | 60,000 | $103.8K |
| Profund Advisors LLC | 50,242 | $86.9K |
| Engineers Gate Manager LP | 35,808 | $61.9K |
| Verition Fund Management LLC | 34,098 | $59.0K |
| Virtus ETF Advisers LLC | 31,597 | $54.7K |
| SG Americas Securities, LLC | 28,498 | $49.0K |
| Axq Capital, LP | 22,432 | $38.8K |
| E Fund Management Co., Ltd. | 17,844 | $30.9K |
| Ground Swell Capital, LLC | 14,660 | $25.4K |
| Two Sigma Investments, LP | 12,300 | $21.3K |
| Skopos Labs, Inc. | 4,500 | $7.79K |
| Rothschild Investment LLC | 130 | $225 |
| R Squared Ltd | 130 | $225 |
| Lazard Asset Management LLC | 154 | $0 |
Not filed for Q1 2025 yet (1)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 546,414 | $945.3K |